Drug
Fh1 2 UG
Fh1 2 UG: highest development phase Phase 1, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| fH1 2 ug NCT06460064 | Phase 1 | Influenza |
Latest
No recent events.
Follow Fh1 2 UG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.